VMD Stock Moved to Restricted Trading on HOSE From September 16, 2026

Overview

Y Dược phẩm Vimedimex (ticker VMD, HOSE) will have its shares transferred from controlled status to restricted trading status effective September 16, 2026, according to Decision No. 702/QĐ-SGDHCM dated September 9, 2026, issued by the General Director of the Ho Chi Minh City Stock Exchange. The move follows continued violations of information disclosure regulations after the exchange had already placed the stock under control.

Key Facts

• VMD moves from controlled status to restricted trading status from September 16, 2026, per Decision No. 702/QĐ-SGDHCM dated September 9, 2026.
• The stated cause is continued violation of information disclosure regulations on the securities market after the stock was placed under control.
• VMD remains under warning status per Decision No. 327/QĐ-SGDHCM dated April 17, 2026, linked to a qualified (except-for) audit opinion on the reviewed 2025 consolidated financial statements.
• A prior restricted-trading decision, No. 937/QĐ-SGDHCM dated October 16, 2025, was also tied to disclosure violations.
• On September 8, 2026, VMD submitted a written explanation and remediation progress report to HOSE.
• VMD says the reviewed H1 2026 financial statements were filed and disclosed, with an unqualified (full acceptance) audit opinion.
• The company says it completed its H1 2026 corporate governance report and governance information form, committing to full disclosure before September 10, 2026.
• VMD shares closed at 13,800 on September 10, 2026.

What Happened

Y Dược phẩm Vimedimex notified the market of the status change for its VMD shares. Under Decision No. 702/QĐ-SGDHCM, signed by the General Director of the Ho Chi Minh City Stock Exchange on September 9, 2026, the stock shifts from the controlled category to the restricted trading category starting September 16, 2026. The exchange cited the listed entity’s continued breach of information disclosure rules after the securities had already been placed under control.

The company had earlier received a series of HOSE decisions: placing the stock under warning, moving it from warning to control, and reminding it of late disclosure of quarterly financial statements and the H1 2026 corporate governance report. In its September 8, 2026 filing, VMD said it had completed and disclosed the reviewed H1 2026 financial statements, which carried an unqualified audit opinion, and had prepared its H1 2026 governance reports in the required formats. The company committed to publishing any outstanding items as soon as possible and to meeting its 2026 disclosure obligations.

Market Context

VMD trades on HOSE in the pharmaceuticals segment of the health care sector. The shares closed at 13,800 on September 10, 2026, the session after the exchange decision was dated. Restricted trading status on HOSE typically narrows the permitted trading session for the stock, which can reduce liquidity and widen the spread between bid and ask. The sequence of warning, control and now restricted status places VMD among the exchange’s more heavily flagged listings, a group that generally draws heightened scrutiny from domestic and foreign institutional investors screening for governance risk.

Strategic Significance

For long-term investors, the core issue is governance and disclosure reliability rather than the underlying pharmaceutical distribution business. A restricted-trading designation signals that the exchange regards the company’s reporting discipline as unresolved even after a remediation process, and it follows a qualified audit opinion on the reviewed 2025 consolidated statements. That combination raises the discount rate investors should apply to reported earnings and complicates any thesis built on a re-rating of the shares. The company’s claim of an unqualified opinion on the reviewed H1 2026 statements is a positive data point, but the exchange’s action indicates the broader disclosure record has not yet been normalized.

What to Watch

• HOSE decisions on whether VMD is returned to controlled or normal trading status, and the timing of any such review.
• The company’s 2026 quarterly and annual disclosure filings, including whether deadlines are met without reminders.
• The audited full-year 2026 financial statements and whether the audit opinion remains unqualified.
• Any further HOSE reminders or penalties regarding late or incomplete disclosure.
• Trading liquidity and price behavior in VMD after September 16, 2026, relative to the September 10 close of 13,800.